ProfileGDS5678 / 1457421_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 43% 43% 43% 52% 45% 43% 42% 42% 42% 44% 40% 41% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1002145
GSM967853U87-EV human glioblastoma xenograft - Control 22.9891243
GSM967854U87-EV human glioblastoma xenograft - Control 32.9910443
GSM967855U87-EV human glioblastoma xenograft - Control 42.9393243
GSM967856U87-EV human glioblastoma xenograft - Control 53.2258152
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1473245
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0529643
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9569942
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9430542
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9602442
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0244644
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.87840
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9539941
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9620642